Skip to main content

Table 2 Clinical characteristics

From: Clinical characteristics of Pneumocystis pneumonia in non-HIV patients and prognostic factors including microbiological genotypes

 

All patients

Survivors

Non-survivors

 

Characteristics

(n = 82)

(n = 62)

(n = 20)

P value

Corticosteroids

65

(79%)

48

(77%)

17

(85%)

0.55

   Daily dose, mg

13

(10-23)

13

(10-25)

15

(11-20)

0.39

   Less than 10 mg/day

24

(29%)

20

(32%)

4

(20%)

0.40

   Total duration, days

152

(66-943)

153

(67-889)

147

(38-2346)

0.95

   Less than 1 month

7

(9%)

4

(6%)

3

(15%)

0.35

Immunosuppressive agents

41

(50%)

35

(56%)

6

(30%)

0.07

Antitumor chemotherapy

22

(27%)

14

(23%)

8

(40%)

0.15

PCP Prophylaxis

3

(4%)

1

(2%)

2

(10%)

0.15

Lower respiratory symptoms

74

(90%)

55

(89%)

19

(95%)

0.67

Fever

56

(68%)

42

(68%)

14

(70%)

1.00

Hypoxemia

57

(70%)

39

(63%)

18

(90%)

0.03

PaO2/FiO2 ratio (n = 50)

277

(168-341)

304

(186-356)

183

(108-318)

0.07

SOFA score

2

(1-4)

2

(1-3)

3

(1-5)

0.11

Laboratory findings

       

   Neutrophils,/mm3

6750

(5000-9525)

6250

(4975-8700)

8100

(5475-15425)

0.06

   Lymphocytes,/mm3

545

(400-1100)

750

(475-1225)

500

(200-675)

0.03

   Thrombocytes,/mm3

15.9

(11.5-24.7)

16.2

(12.2-25.3)

14.3

(7.3-24.7)

0.20

   C-reactive protein, mg/dL

6.4

(2.5-10.7)

5.6

(2.5-9.6)

8.5

(2.1-13.6)

0.18

   Albumin, mg/dL

2.8

(2.4-3.2)

2.9

(2.5-3.3)

2.3

(2.2-2.9)

0.007

   Creatinine, mg/dL

0.9

(0.6-1.3)

0.9

(0.6-1.2)

0.9

(0.6-1.6)

0.53

   Blood urea nitrogen, mg/dL

21

(16-31)

20

(15-27)

30

(16-63)

0.25

   Total bilirubin, mg/dL

0.6

(0.4-0.9)

0.6

(0.4-0.8)

0.7

(0.5-0.9)

0.43

   Lactate dehydrogenase, IU/L

394

(303-501)

368

(291-485)

456

(366-662)

0.007

   LDH > upper limit of normal value

76

(93%)

56

(90%)

20

(100%)

0.33

   β-D-glucan (n = 81), pg/mL

39.7

(14.5-207.5)

36.3

(15.0-204.7)

53.6

(11.3-353.7)

0.50

   β-D-glucan (n = 81) >11 pg/mL

65

(80%)

49

(79%)

15

(79%)

1.00

Initial Treatment

       

   TMP-SMX

77

(94%)

58

(94%)

19

(95%)

1.00

Drug change

19

(25%)

13

(22%)

6

(32%)

0.54

   Pentamidine

5

(6%)

4

(6%)

1

(5%)

1.00

Drug change

1

(20%)

1

(25%)

0

(0%)

1.00

   Adjunctive steroid therapy

60

(73%)

44

(71%)

16

(80%)

0.57

Anti-cytomegalovirus therapy

23

(28%)

15

(24%)

8

(40%)

0.25

Mechanical ventilation

22

(27%)

9

(15%)

13

(65%)

<0.001

Pneumothorax

4

(5%)

1

(2%)

3

(15%)

0.04

Invasive pulmonary aspergillosis

5

(6%)

1

(2%)

4

(20%)

0.01

  1. Data are presented as the No. (%) or median (interquartile range). Steroid dosages are expressed as corresponding amounts of prednisolone. Categorical variables were compared using Fisher's exact test, and continuous variables were compared using the Mann-Whitney U test.
  2. PCP: pneumocystis pneumonia; SOFA: Sequential Organ Failure Assessment; LDH: lactate dehydrogenase; TMP-SMX: trimethoprim-sulfamethoxazole.
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us